The era of reduced-intensity allogeneic stem cell transplantation, with its emphasis on older patients, has created new challenges in the management of what is now an older related stem cell donor population. These donors are now on average no less than 10 years older than in the mid-1990s. Donors over 70 years of age are no longer isolated or exceptional cases. They may still be considered eligible for donation but many of them, based on the older age and their medical history, may no longer fully qualify as 'healthy' or 'normal'. The older the donor, the more likely that hematologic abnormalities, comorbidities and treated malignancies will complicate the picture. Assessing the risk-benefit ratio for both donor and recipient can now be more challenging than ever.
INTRODUCTION
The number of allogeneic stem cell transplants for treatment of malignant hematologic disorders in older patients continues to increase. According to the Center for International Blood and Marrow Transplant Research (CIBMTR) database (collecting data from over 450 transplant centers worldwide), 22% of allogeneic transplant recipients in the 2007-2013 period were 60 years or older. In the previous 5-year period (2000) (2001) (2002) (2003) (2004) (2005) (2006) , the same percentage was 10% (a 2.2-fold increase) ( Figure 1 ). 1, 2 This trend towards transplanting older recipients is such that while their related donors (usually of comparable age) may frequently still be eligible for donation, based on their age and medical history, many of them may no longer fully qualify as 'normal' or 'healthy'.
As such, the evaluation and management of normal related bone marrow (BM) and PBSC donors currently poses new and unique challenges in addition to the well-established ones. Although the eligibility criteria for unrelated (or registry) donors usually include an upper age limit and strict rules for medical approval (or deferral), due to the different context, the situation with related donors is markedly different. Donors born in the 1960's and even 1970's are now routinely considered, although not necessarily cleared for donation.
This manuscript will focus on these older donors. Its intent is not to provide the reader with a detailed and comprehensive review of how donor age affects the stem cell product being procured and therefore transplantation outcome in the recipient (e.g. engraftment, GvHD, survival). It is also not meant to provide stringent statements or general guidelines, as in most instances there is simply not enough data on these older donors to support them. Its aim is to pose and attempt to answer 10 practical and clinically relevant questions by reviewing some of the data currently available, with the understanding that these data can sometimes be sketchy and insufficient, particularly for donors over 70 years of age.
HOW OLD ARE RELATED DONORS CURRENTLY?
The Related Donor Safety Study (RDSafe: NCT00948636) prospectively enrolled related stem cell donors during the 2010-2014 period at 53 pediatric and adult transplant centers in the United States.
3-5 A total of 1680 related donors were accrued. Their median age was 48 years (range 0-79), with BM donors being younger than PBSC ones (median age 14 vs 53 years). The BM to PBSC donor ratio was 1:3. Of these donors, 464 (28%) were between 51 and 60 years of age and 265 (15%) were older than 60 years. Of these donors above age 60 years, 153 were 61-65 years of age (9%), 84 were 66-70 years of age (5%) and 28 were 71 years of age or older (2%). These data provide a snapshot of current practice at major transplant centers across the United States (M Pulsipher, personal communication, March 2016).
At the University of Texas MD Anderson Cancer Center, the median age for related donors has fluctuated over the past 15 years, but has consistently remained in the 40-50 year range ( Figure 2 ). In 2014 and 2015, the median age was 52 (range and 49 (range 9-75) years, respectively, with 28% (n = 33) and 19% (n = 29) of them of age 60 years or older (P Anderlini, unpublished data). To put this in historical perspective, during the 1994-1998 period the median age for BM and PBSC donors reported to the CIBMTR and/or the European Group for Blood and Marrow Transplantation was 32 and 38 years, respectively. Of these donors, 75% of the BM and 99% of the PBSC donors were related ones. biological continuum. Establishing some kind of age cutoff, if agreed upon, could be used to prompt appropriate referrals (maybe as part of a separate evaluation track) for the workup of these 'older' donors.
SHOULD THERE BE AN UPPER AGE LIMIT FOR NORMAL RELATED DONORS?
Such an upper age limit, if implemented, would not be based on any widely accepted scientific rationale. An informal poll conducted among nine major adult US transplant centers involved in a recently published clinical trial 8 failed to disclose any instance where an upper age limit is present and enforced (unless protocoldriven) (P Anderlini, unpublished data, March 2016). Therefore, there seems to be little enthusiasm in the stem cell transplant community for this. 9 That said, I believe most transplanters (myself included) will admit to a higher level of anxiety and nervousness (as well as taking a more cautious approach) when dealing with related donors in the late 60's and in the 70's, particularly if they have multiple and/or significant comorbidities. It goes without saying that decisions about donor eligibility (or lack of) should not be based on age alone.
DO OLDER DONORS MOBILIZE PBSCS MORE POORLY, AND IF SO, WHY?
The older the donor, the more likely that PBSC collection will be selected in lieu of marrow harvesting. A body of literature has shown that older donors do not mobilize PBSCs as efficiently as younger ones. [10] [11] [12] [13] One study in mice suggests that a depleted stem cell marrow reserve is not the culprit.
14 A separate study in humans indicated that the frequency of hematopoietic stem cells (HSCs, defined as CD45 hi /CD34 + and CD45 hi /CD133 + ) in femoral and trochanteric BM actually increases with age. 15 Aging affects HSCs in a number of ways. [16] [17] Some kind of selective, age-acquired mobilization defect may be responsible, although this has not been fully established. Still, in the vast majority of cases a CD34+ cell dose deemed sufficient for allotransplantation will be collected in the end, sometimes adding plerixafor to granulocyte CSF. 10, 11, 18 Experience with plerixafor in normal donors is limited, however, and its use should preferably be restricted to clinical trials (as it is the case at our center). Once again, it should be pointed out that very few donors in these studies were 70 years or older.
ARE OLDER STEM CELL DONORS HEMATOLOGICALLY 'NORMAL'?
This is the most scientifically intriguing and current question among the ones listed and will be explored in more detail. It has been known for some time that aging has a profound impact on the hematopoietic as well as immune system, particularly on T cells. 19 Age-related clonal hematopoiesis has now been convincingly demonstrated, [20] [21] [22] [23] although an exhaustive review of this rapidly expanding area and its implications is beyond the scope of the present report. 24 Clonal hematopoiesis was documented as early as 1997 in 23% of a group of 65 normal elderly women (mean age 76 years, range 63-95). 20 More recently, a study found that in older subjects, somatic mutations detectable by DNA sequencing were rare under the age of 40 years, but became far more common in older age groups, particularly after the age of 60 years. Mutations in genes related to hematologic cancers were detected in 5.6% and 9.5% of individuals 60-69 and 70-79 years of age, respectively. 21 It is possible that some of these mutations may account for the hypothetical age-related stem cell mobilization defect (see 'Do older donors mobilize PBSCs more poorly, and if so, why?'). The presence of such mutations was linked to a higher risk of hematologic cancers and an increase in all-cause mortality. 21 However, there is as yet no evidence that recipients of stem cell products from these donors will be at risk for hematologic malignancies. Moreover, DNA sequencing in older donors would be costly and impractical and unlikely to be cost-effective, at least with currently available techniques.
Normal aging has been linked with the progressive shortening of telomeres in HSCs, particularly under conditions with specific Considerations on older related stem cell donors P Anderlini mutations in the telomerase gene complex. 25, 26 The role of telomeres in disease, aging and cancer has been reviewed recently in detail and will not be discussed further here. 25 Telomere shortening or dysfunction can affect the longevity and self-renewal capacity of HSCs. 25, 26 This raises the possibility of HSC exhaustion under the stress of a regenerating marrow post transplant. This could potentially lead to late-onset cytopenias and graft failure in recipients of stem cell products from elderly donors. This remains a purely theoretical concern at this time, although it should not be ignored, particularly when evaluating donors over the age of 70 years.
MGUS is a well-established premalignant condition. [27] [28] [29] [30] The actual prevalence of MGUS is known to be age-related. It is estimated to be 2.3%, 3.8% and 5.8% at age 60, 70 and 80 years, respectively, although not all cases are clinically detected. 28 It is believed that, when first clinically recognized, MGUS has likely been present in an undiagnosed state for up to 10 years or longer. 28 The risk of progression to a lymphoproliferative disorder (usually multiple myeloma) is highly variable and is determined by factors such as the abnormal free light-chain ratio, M-protein type (IgG vs non-IgG) and concentration, as well as the reduction of one or two noninvolved Ig isotype levels (the so-called immunoparesis). [27] [28] [29] [30] In the original report by Kyle et al., 27 the risk of progression was estimated to be~1% per year. In low-risk cases (e.g. o 1.5 g/dL IgG M-protein and no serum-free light chain), the risk is 0.25-0.4% per year. 29 In another study covering the 1963-2000 time period (728 MGUS cases followed for up to 30 years), 84 patients developed a lymphoid malignancy, for a 30-year cumulative risk of 15.4%. In about two-thirds (i.e. 63%) of cases it was multiple myeloma. 30 MGUS should be identifiable during the laboratory workup of the donor, but cases may be missed or overlooked (particularly if the M-protein level is low). That said, to my knowledge, there is no published evidence that infusion of stem cell products from a donor with undiagnosed MGUS translates into a higher risk of monoclonal gammopathy in the recipient.
A similar scenario is provided by monoclonal B-cell lymphocytosis (MBL). MBL is a condition characterized by the presence of circulating monoclonal B cells in otherwise healthy individuals. 31, 32 Most MBL clones have an immunophenotype resembling typical CLL. MBL is believed to be a precursor to CLL. 31, 32 In one large study in blood donors, the prevalence estimate of MBL was found to be 8.1% and 10.7% in donors aged 55-64 and over 65 years, respectively. 31 Although the natural history of MBL is still not well defined, the risk of progression seems largely restricted to subjects with larger B-cell clones ('clinical MBL', 4500 monoclonal B cells per μl). In these donors, the risk of progression to CLL requiring therapy is 1-2% per year. 32 While this finding is of concern, a separate study has suggested that MBL transmission does not meaningfully contribute to the risk of CLL in recipients of blood transfusions. 33 The situation may be different, however, in stem cell transplant recipients. MBL may or may not be detected during the laboratory workup of the donor, which would not be expected to include immunophenotyping of the peripheral blood. An abnormally high circulating lymphocyte count should prompt further testing.
Last, in a small 1995 study, healthy blood donors (six out the nine tested) were found to have circulating blood cells with the t(14;18) translocation often found in follicular lymphoma. 34 A later, larger study involving 5 20 000 healthy participants identified 218 subjects (0.04%; median age 54 years) with the t(14;18) translocation. As many as 100 of them developed follicular lymphoma between 2 and 161 months after enrollment. 35 The authors concluded that detection of high t(14;18) frequency in blood from healthy individuals translates into a 23-fold higher risk of subsequent follicular lymphoma. This higher risk was durable, for up to 15 years before diagnosis. 35 In an intriguing case report involving the t(11;14) translocation frequently associated with mantle-cell lymphoma, it took at least 10 years for a stem cell donor (aged 61 years at the time of donation) with a retrospectively identified translocation to develop mantle-cell lymphoma. 36 While intriguing, these findings are of limited relevance to the evaluation of older donors. Screening for the t (14:18) or other translocations is highly unlikely to be costeffective, and it is unclear whether the infusion of a stem cell product containing cells carrying chromosomal translocations linked with lymphoma or leukemia will eventually lead to malignancy. It may be considered in donor-patient pairs with a positive family history for leukemia or lymphoma.
All of these data could lead to the conclusion that older donors should undergo a different type of screening, including a BM assessment. This issue remains controversial. [37] [38] [39] The likelihood of detecting a clinically relevant malignant or premalignant disease not recognized or suspected based on routine screening is exceedingly low. 37 
OLDER DONORS ARE LIKELY TO HAVE MORE COMORBIDITIES. WHAT IMPACT (IF ANY) DO THESE HAVE?
Strictly speaking, the term 'comorbidity' should be reserved to patients, but it can be practical and useful when applied to donors as well. Data on this topic are very sketchy. In one study, comorbidities did not significantly affect mobilization, although performance status may have been a factor. 12 However, in this study, virtually no donor was older than 70 years. Recipients are now routinely stratified according to the CoMorbidity-Age Index to predict mortality risk after transplant. 40 Ideally, a similar approach could be applied to donors as well, to assess the risk of donation-associated morbidity and mortality.
The comprehensive management of these older donors can often require a strong and up-to-date background in internal medicine (and sometimes even geriatric medicine) that not all transplant physicians possess. It is the practice at our center to refer these older donors with significant comorbidities to our Internal Medicine Department (which includes relevant subspecialties such as Cardiology) for evaluation and treatment (if needed).
HOW DO THESE OLDER DONORS TOLERATE THE DONATION PROCESS?
This question has been the focus of the recently completed RDSafe Study. [3] [4] [5] Although not all the data have been published in peer-reviewed manuscripts, initial results suggest that older (460 years) donors have high rates of baseline and donation-related pain and slow recovery. 4 The RDSafe database includes comorbidity data, which should help with the question 'Are older stem cell donors hematologically 'normal'?'. It should be added that unrelated donors (only up to age 60 years) were used as comparators in this project. It has been shown that older age is associated with a higher chance of requiring more than one day of collection (P = 0.017), 12 and this can clearly affect the tolerability of the procedure.
SOME OF THESE OLDER DONORS ARE CANCER SURVIVORS. DOES IT MATTER?
Older donors are more likely than younger ones to have a history of treated cancer, particularly breast, prostate, melanoma and Hodgkin or non-Hodgkin lymphoma. Cancer survivors will have been exposed to chemotherapy or hormonal therapy and sometimes radiation therapy as well. A commonly adopted (but totally arbitrary) rule of thumb is to allow donors with prior malignancies (except resected basal cell carcinoma or treated carcinoma in situ), provided they have been cancer-free for a minimum of 5 years. However, selected cases may be approached differently, depending on the expected risk of recurrence (which can often be accurately quantified), as well as the availability (or lack of) of alternative donors. One should keep a high index of suspicion for therapy-related myelodysplasia or acute myeloid leukemia. Any cytopenia or abnormality in the peripheral blood should prompt an additional review of their history and hematology profile as well as a low threshold for additional testing, including cytogenetic and molecular ones. 41, 42 It is now accepted that, whenever logistically and practically feasible, the care of related donors and their intended recipients should not be the responsibility of the same transplant physician. This separation concept was incorporated in the Fifth Edition (and retained in the recently released Sixth Edition) of the Foundation for the Accreditation of the Cellular Therapy and the Joint Accreditation CommitteeInternational Society for Cellular Therapy and European Society for Blood and Marrow Transplantation International Standards. 43 It is encouraging to see that significant progress has been made in this area since the original US survey, 44, 45 which suggested a potential conflict of interest in over 70% of transplant centers in the United States. If the donation-related risks are perceived to be higher than average due to donor age and comorbidities, it would seem even more important to insulate the donor from the transplant physician caring for the patient.
IF THE DONOR IS OLDER AND HAS

IS A YOUNG (E.G. <30 YEARS) MATCHED UNRELATED DONOR A PREFERRED ALTERNATIVE?
This is an emerging and clinically relevant question. Two recent studies have looked at this issue. 46, 47 In a CIBMTR registry analysis on patients with various hematologic malignancies, outcomes (i.e. non-relapse mortality, relapse and overall mortality) for recipients with good performance status were better with an older related donor. In patients with poor performance status, outcomes were similar regardless of the donor used. In this report, 38% of the related donors were 60 years of age or older. Only a few (5%) were older than 70 years. 46 In a separate registry (EBMT) study on patients with high-risk myelodysplasia only, use of a young matched unrelated donor was associated with improved survival. The median related donor age in this study was 56 (range years. The percentage of donors over 70 years was not provided. 47 Drawbacks in both of these studies have been pointed out. 2 In the real world, decisions will have to be made on a case-by-case basis, taking into account multiple donor-and recipient-related factors. In selected cases, an haploidentical donor can provide a viable alternative option. In principle, the older the related donor (e.g. 470 years), the stronger the rationale for considering a young matched unrelated (or haploidentical) donor as an alternative.
CONCLUSION
It is a brave new world for related stem cell donors. They are on average no less than 10 years older than their predecessors of the mid-1990's, and donors over 70 years are no longer isolated or exceptional cases. These older donors present unique challenges related to the impact of aging on the hematopoietic, immune and other organ systems, as well as the likelihood of subclinical or treated malignancies. These age-related developments should not necessarily disqualify them, but should prompt stem cell transplant physicians to pursue a more careful assessment of the risk-benefit ratio for both donor and recipient.
